Exome sequencing data were available for blood and matched tumor DNA from four metastatic lesions of this patient, two excised before (Mel5-pre1 and Mel5-pre2) and two after therapy (Mel5-post1 and Mel5-post2) with BRAF/MEK inhibitors. This evidence concerns the gene MAP2K7 and neoplasm.